#ScienceLink #Madrid2026 #ESMO26 #DUOE #CancerDeEndometrio · CBA Frontier Insights

返回会议原文

ScienceLink· @sciencelinkonco · X·2026-10-25 02:42· 11 小时前评分70

正文 · 原文

#ScienceLink #Madrid2026 #ESMO26 #DUOE #CancerDeEndometrio

En el segundo análisis interino de DUO-E (fase III; n=718), durvalumab + carboplatino/paclitaxel, seguido de durvalumab ± olaparib, mostró resultados numéricamente favorables en SG en 1L del cáncer de endometrio avanzado/recurrente.

⏰ Mediana de seguimiento: 52 meses
Madurez de los datos de SG: 52%

📊 Mantenimiento con durvalumab + olaparib vs control
SG: 51.1 vs 39.6 meses
HR 0.77 (IC 95%: 0.60–0.98; p=0.037)
Diferencia numérica entre medianas: 11.5 meses.

📊 Mantenimiento con durvalumab solo vs control
SG: 40.7 vs 39.6 meses
HR 0.87 (IC 95%: 0.68–1.11; p=0.259)

⚠️ Ningún esquema alcanzó significancia estadística en SG. Para el brazo con olaparib, el umbral preespecificado era p<0.0165.

🧬 Subgrupos exploratorios: esquema con olaparib vs control
dMMR: HR 0.43 (IC 95%: 0.21–0.83).
pMMR: HR 0.85 (IC 95%: 0.65–1.11).

Sin nuevas señales de seguridad. El análisis final de SG está pendiente.

🔗Leer/escuchar noticia completa: https://buff.ly/fJHxF7X

8 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2879RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上

Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial

https://esmocongress.esmo.org

4737RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT

https://esmocongress.esmo.org

LBA2按 Presidential Symposium I 对上

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org

LBA26按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial

https://esmocongress.esmo.org

LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

LBA37按 Proffered paper: Gynaecological cancers 对上

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org

来源：ScienceLink · x.com